Adjusting biologic treatments for RA patients in response to the coronavirus pandemic is not as simple as it may seem, a study by UK rheumatologists suggests. Most patients who switched from an intravenous to a subcutaneous delivery of abatacept or tocilizumab in order to reduce face-to-face hospital visits preferred to switch back, largely due to ...
Pandemic-inspired switch in RA treatment leads to worse outcomes
By Dave Levitan
2 Dec 2020